2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
General media enquiries
Contact our global media and communications team at:

Please note – the press team can only answer enquiries from accredited members of the press.
Related articles

Smiths Group becomes member of the Manufacturing Technology Centre
Read our latest company news as Smiths Group becomes a member of the Manufacturing Technology Centre
Find out more
John Crane launches next-generation Coaxial Seal
Find out more
Smiths Group Foundation launches second round of charitable donations
Read our latest company news as the Smiths Group Foundation launches a second round of charitable donations
Find out more